![Dean Marc Slagel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dean Marc Slagel
Directeur Général chez
Esperante BV
Profil
Dean Marc Slagel is currently the Director at Haemostatix Ltd. and the Managing Director & Director at Altacor Ltd. He is also the Managing Director at Esperante BV, Esperante Ltd., Esperante AB, and a Non-Executive Director at Oxford Cancer Biomarkers Ltd. In the past, Mr. Slagel served as the Chief Executive Officer at Esperante Ventures from 2003 to 2007.
He was also the Chairman & Managing Director at Endocells SARL, Director at Pharmaxon SAS, and a Non-Executive Director at Arquer Diagnostics Ltd. Additionally, he served as an Independent Director at CARA Therapeutics, Inc. from 2005 to 2018.
He was also a Director at Atox Bio Ltd., Theryte Ltd., and Novacta Biosystems Ltd. Furthermore, he worked as the Director-Global Business Development at Ferring Pharmaceuticals Ltd. from 1995 to 2004.
He also served as a Director at Canbex Therapeutics Ltd. and as a Principal at Tillotts Pharma AG.
Mr. Slagel obtained an MBA from Ecole Nationale des Ponts et Chaussées in 2000.
Postes actifs de Dean Marc Slagel
| Sociétés | Poste | Début |
|---|---|---|
Esperante BV
 Esperante BV Investment ManagersFinance Esperante is an active manager which makes seed investments in start-up companies primarily in Europe and North America focusing on innovative human therapeutics for the treatment of major diseases and disorders. The firm seeks to invest in companies with a professional management team, therapeutic developments in major indications and which are generating revenue. They prefer to make syndicated investments with appropriate partners, investing up to EUR 500,000 per project per year and remaining open to follow-up financing in subsequent years. Esperante typically takes minority equity stakes and a seat on the board of directors of their investee companies, aiming to exit their investments within three to five years. | Directeur Général | 01/01/2004 |
Altacor Ltd.
 Altacor Ltd. Pharmaceuticals: MajorHealth Technology Operates as a ophthalmology company which develops and markets a portfolio of products in fields of dry eye, glaucoma & ocular infection | Directeur/Membre du Conseil | 03/12/2009 |
Esperante AB | Directeur Général | - |
Oxford Cancer Biomarkers Ltd.
 Oxford Cancer Biomarkers Ltd. Hospital/Nursing ManagementHealth Services Provides cancer treatment services | Directeur/Membre du Conseil | - |
Haemostatix Ltd.
 Haemostatix Ltd. Pharmaceuticals: MajorHealth Technology Designs and develops solutions for haemostasis and thrombosis | Directeur/Membre du Conseil | - |
Esperante Ltd.
 Esperante Ltd. Investment ManagersFinance Esperante Ltd. operates as a venture investment company controlled by C&P Group Holdings. The company was founded on April 29, 1986 and is headquartered in Maidenhead, the United Kingdom. | Directeur Général | 01/01/2004 |
Anciens postes connus de Dean Marc Slagel
| Sociétés | Poste | Fin |
|---|---|---|
Canbex Therapeutics Ltd.
 Canbex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Engages in the development of novel peripherally-acting cannabinoid agonists and mimetics for the treatment of multiple sclerosis spasticity and pain | Directeur/Membre du Conseil | 25/04/2019 |
| CARA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 07/03/2018 |
Pharmaxon SAS
 Pharmaxon SAS Pharmaceuticals: MajorHealth Technology Discovers, develops and markets therapeutic drugs controlling cell mobility | Directeur/Membre du Conseil | 18/12/2012 |
| ░░░░░░░░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Dean Marc Slagel
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
27
Relations au 1er degré
18
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 18 |
|---|---|
CARA Therapeutics, Inc.
 CARA Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes new chemical entities designed to fundamentally change the way acute pain, chronic pain and pruritus are managed | Health Technology |
Tillotts Pharma AG
 Tillotts Pharma AG Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products for gastroenterology & infectious diseases | Health Technology |
Ecole Nationale des Ponts et Chaussées
 Ecole Nationale des Ponts et Chaussées Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Esperante Ventures
 Esperante Ventures Investment ManagersFinance Alternative investment manager | Finance |
Novacta Biosystems Ltd.
 Novacta Biosystems Ltd. BiotechnologyHealth Technology Discovers and develops drugs for treatment of bacterial infections | Health Technology |
Haemostatix Ltd.
Haemostatix Ltd. Pharmaceuticals: MajorHealth Technology Designs and develops solutions for haemostasis and thrombosis | Health Technology |
Esperante Ltd.
Esperante Ltd. Investment ManagersFinance Esperante Ltd. operates as a venture investment company controlled by C&P Group Holdings. The company was founded on April 29, 1986 and is headquartered in Maidenhead, the United Kingdom. | Finance |
Esperante BV
Esperante BV Investment ManagersFinance Esperante is an active manager which makes seed investments in start-up companies primarily in Europe and North America focusing on innovative human therapeutics for the treatment of major diseases and disorders. The firm seeks to invest in companies with a professional management team, therapeutic developments in major indications and which are generating revenue. They prefer to make syndicated investments with appropriate partners, investing up to EUR 500,000 per project per year and remaining open to follow-up financing in subsequent years. Esperante typically takes minority equity stakes and a seat on the board of directors of their investee companies, aiming to exit their investments within three to five years. | Finance |
Theryte Ltd.
 Theryte Ltd. Pharmaceuticals: MajorHealth Technology Operates as a drug discovery and development company that is committed to bringing new cancer treatments to market | Health Technology |
Canbex Therapeutics Ltd.
Canbex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Engages in the development of novel peripherally-acting cannabinoid agonists and mimetics for the treatment of multiple sclerosis spasticity and pain | Health Technology |
Endocells SARL
 Endocells SARL BiotechnologyHealth Technology Develops a technology platform for the generation and development of human endocrine cell lines | Health Technology |
Pharmaxon SAS
Pharmaxon SAS Pharmaceuticals: MajorHealth Technology Discovers, develops and markets therapeutic drugs controlling cell mobility | Health Technology |
Altacor Ltd.
Altacor Ltd. Pharmaceuticals: MajorHealth Technology Operates as a ophthalmology company which develops and markets a portfolio of products in fields of dry eye, glaucoma & ocular infection | Health Technology |
Arquer Diagnostics Ltd.
 Arquer Diagnostics Ltd. Medical/Nursing ServicesHealth Services Develops proprietary diagnostic immunoassays for the detection of prostate and bladder cancer using urine samples | Health Services |
Atox Bio Ltd.
 Atox Bio Ltd. BiotechnologyHealth Technology Provides novel immune modulators for critically ill patients with severe infections | Health Technology |
Esperante AB | |
Ferring Pharmaceuticals Ltd.
 Ferring Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and produces pharmaceutical products | Health Technology |
Oxford Cancer Biomarkers Ltd.
Oxford Cancer Biomarkers Ltd. Hospital/Nursing ManagementHealth Services Provides cancer treatment services | Health Services |
Choisissez Zonebourse 
